Critically, our signature’s clinical applicability is reinforced by experimental validation: mRNA levels of key genes (e.g., GHR, BTC) were confirmed via RT-qPCR in HCC cell lines, while HPA-derived IHC data revealed prognostic protein expression patterns (e.g., HDAC1, MAPT). This evidence concerns the gene HDAC1 and hepatocellular carcinoma.